Search This Blog

Friday, November 6, 2026

Cg Oncology beats, confirms near-term cretostimogene Ph 3 readouts, BLA timeline

 

Cg Oncology Inc reports fiscal Q3 2026 results with revenue $1.6M (-4% YoY), beats revenue estimates

  • Third-quarter 2026 results include $984.5 million in cash, sufficient to fund operations through 2029.
  • Company confirmed near-term cretostimogene Phase 3 data readouts and BLA timeline for BCG-unresponsive NMIBC following Q3 2026 results.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)